# Nuformix to raise £150,000 for NXP002 programme

- Link: https://www.directorstalkinterviews.com/__trashed/4121145464
- Published: 2024-03-01T07:12:56+00:00
- Author: Amilia Stone

**Nuformix plc **([LON:NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l)),
a pharmaceutical development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing, has announced a subscription to raise gross proceeds
of £150,000 through a subscription for 75,000,000 new ordinary shares of 0.1 pence
in the capital of the Company at a price of 0.20 pence per share.  The New Ordinary
Shares will represent approximately 9.2 per cent. of the Company’s enlarged issued
share capital and are being issued pursuant to the Company’s existing share issuance
authorities.

The net proceeds of the Subscription will be used by the Company primarily to further
advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis(
IPF).

**Commenting, Dr Dan Gooding, Executive Director of Nuformix, said:** _“The funds
raised through the Subscription will support the Company as we focus on discussions
with potential licensees and the overall progression of the NXP002 programme to 
improve the treatment of IPF via inhalation.  I look forward to providing further
updates in due course.”_

**Admission and Total Voting Rights**

Application will be made for the 75,000,000 New Ordinary Shares to be admitted to
the Official List of the FCA and to trading on the Main Market of the London Stock
Exchange (“Admission”). It is expected that Admission will become effective and 
that unconditional dealings will commence on the London Stock Exchange at 8.00 a.
m. on 6 March 2024.

Following Admission of the New Ordinary Shares, the total number of Ordinary Shares
in issue will be 819,309.368, each with one voting right.  Nuformix does not hold
any rights in treasury.  The total voting rights figure is therefore 819,309,368
and can be used by shareholders as the denominator for the calculations by which
they will determine whether they are required to notify their interest in, or a 
change of their interest in, the Company under the Disclosure Guidance and Transparency
Rules of the Financial Conduct Authority.

Share on:
